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The need for new drugs, diagnostics and vaccines has changed over the past decade 
for many of neglected infectious diseases (NIDs). NIDs can be viewed in three 
categories: (a) those for which there is some market, some commercial and public health 
incentive, eg. malaria and tuberculosis, (b) those for which tools are available and 
implementation is required, eg. some helminth and bacterial diseases, and (c) those for 
which tools are not available and for which drug R & D is limited, the “most neglected 
diseases”, for example, the dengue, leishmaniases and trypanosomiases, have very 
different requirements.   
  
Three main factors have been responsible for this decade of change: (i) the growth of 
Public Private Partnerships (more particularly, Product Development Partnerships; 
PDPs), (ii) the re-engagement of the some parts of the pharmaceutical industry in 
different models of collaboration, and (iii) a re-focus of academic groups on translational 
medicine within dedicated centres. For drug development, most changes so far has 
come through the PDPs, in particular in the Medicines for Malaria Venture, the Drugs for 
Neglected Diseases initiative the TB Alliance, which manage substantial funding through 
a portfolio approach to drug development. A substantial amount of the funding, so far, 
has come from philanthropic organizations, especially the Bill and Melinda Gates 
Foundation.   
       
The endgame is not just the registration of a new drug but to ensure that the drug 
becomes an effective treatment, with the need to ensure delivery, compliance, safety 
tolerability and performance (pharmacovigilance) and access at affordable prices. We 
Other partnerships have ensured that tools for example ivermectin, albendazole, 
azithromycin and praziquantel, that have had a major impact on the control and/or 
elimination of onchocerciasis, lymphatic filariasis, intestinal helminthes, trachoma and 
schistosomiasis,  have become available.  
 
